康方(09926.HK)续涨11%再创纪录高 公布自主研发胃癌药及与中生研发肝癌药具良好安全耐受
康方生物-B(09926.HK)公布与中生制药(01177.HK)共同研发治疗晚期肝癌及核心自主研发治疗晚期胃癌药的最新研发结果显示出良好安全耐受性。康方承昨天股价考验10天线获支持倒升势,今天再创纪录高,最高见56.7元,现造55元,续涨11%,成交619万股,涉资3.38亿元;中生继昨天股价扭六连跌重越10天线後,今早进一步升破50天及20天线,最高见7.78元,现造7.68元,续升4.2%,成交7,663万股,涉资5.87亿元。
康方生物公布,与中生制药共同研发的抗PD-1单抗药物派安普利(安尼可)联合安罗替尼一线治疗晚期肝癌(HCC)的最新研究在2021年国际胃肠道癌症研讨会上发布。研究认为,派安普利联合安罗替尼组合安全耐受,作为晚期HCC患者的一线治疗表现出令人鼓舞的抗肿瘤活性。
此外,康方核心自主研发兼全球首创的新型肿瘤免疫治疗双特异性抗体新药Cadonilimab联合化疗一线治疗晚期胃癌或胃食管结合部腺癌的Ib/II期临床研究最新结果在2021年国际胃肠道癌症研讨会上发布。研究显示,Cadonilimab10毫克/千克每两星期一次(Q2W)联合化疗一线治疗GC或GEJ显示出良好的安全性和耐受性。与化疗联合一线治疗GC或GEJ,Cadonilimab在各剂量水平下均表现出令人鼓舞的抗肿瘤活性、持续的肿瘤应答,并可改善晚期GC患者的无进展生存期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.